Tirzepatide Linked to Severe Hyponatremia in Patient with Vasopressin Deficiency
Background
Hyponatremia, a condition characterized by dangerously low sodium levels in the blood, can lead to serious neurological complications. Patients with arginine vasopressin deficiency (AVP-D), formerly known as central diabetes insipidus, are particularly vulnerable due to impaired water balance regulation, often requiring treatment with desmopressin (a synthetic analog of vasopressin). This specific patient's AVP-D was caused by a recurrent Rathke cleft cyst (RCC), a benign brain cyst that can disrupt pituitary function. While tirzepatide, a dual GIP/GLP-1 receptor agonist, is highly effective for weight loss and type 2 diabetes, its potential to induce hyponatremia, especially in predisposed individuals, is not well-understood. This case report addresses the critical knowledge gap regarding tirzepatide-associated severe hyponatremia in patients with pre-existing AVP-D.
Study Design
Results
The 53-year-old female patient presented with asymptomatic severe hyponatremia, with her serum sodium level recorded at 121 mEq/L (milliequivalents per liter), significantly below the normal reference range of 135-145 mEq/L. This marked reduction in sodium occurred after several months of tirzepatide use. Upon review of existing medical literature, this case represents only the third documented instance of severe hyponatremia, defined as a serum sodium level of ≤125 mEq/L, reported in association with tirzepatide therapy globally. Critically, this is the first reported case of tirzepatide-associated severe hyponatremia occurring in an individual with pre-existing arginine vasopressin deficiency (AVP-D). The combination of tirzepatide's potential effects on fluid balance (e.g., nausea leading to increased water intake, or direct renal effects) with the impaired water excretion characteristic of AVP-D patients on desmopressin likely contributed to this severe electrolyte imbalance. This case highlights a unique and significant risk, as it is the first documented occurrence of severe hyponatremia linked to tirzepatide in a patient with pre-existing arginine vasopressin deficiency, underscoring a critical interaction.
Why It Matters
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores the critical importance of heightened clinician vigilance for potential hyponatremia in individuals receiving tirzepatide, especially those with pre-existing conditions like arginine vasopressin deficiency (AVP-D), who are already predisposed to electrolyte imbalances. Furthermore, it emphasizes the necessity for proactive patient education regarding the symptoms of hyponatremia and the implementation of 'desmopressin escape strategies' (e.g., temporary reduction or cessation of desmopressin, fluid restriction) if symptoms arise. This case strongly suggests that clinicians should carefully consider reductions in desmopressin dosing when co-administering with tirzepatide to mitigate the risk of severe hyponatremia, potentially leading to revised clinical guidelines for managing this specific patient population.